India could ship vaccines to COVAX in a few weeks, say sources By Reuters

© Reuters. FILE PHOTO: A health official draws a dose of the AstraZeneca’s COVID-19 vaccine manufactured by the Serum Institute of India, at Infectious Diseases Hospital in Colombo, Sri Lanka January 29, 2021. REUTERS/Dinuka Liyanawatte//File Photo

By Krishna N. Das

NEW DELHI (Reuters) – India could resume deliveries of COVID-19 shots to global vaccine-sharing platform COVAX in a few weeks for the first time since April, two health industry sources said, ending a suspension of supplies that has hurt poor countries.

The World Health Organization (WHO), which co-leads COVAX, has been urging India to restart supplies for the programme, especially after it sent about 4 million doses to its neighbours and partners in October.

Based on an informal approval from India, COVAX officials have started planning allocations of the Covishield shot for various countries, said one of the sources, both of whom declining to be identified pending a final agreement.

Covishield is a licensed version of the AstraZeneca (NASDAQ:) shot made by the Serum Institute of India (SII), the world’s biggest vaccine maker.

SII has nearly quadrupled its output of Covishield to up to 240 million doses a month since April, when India stopped all exports in order to inoculate its own people during a surge of cases.

“There will need to be purchase orders confirmed to SII, labelling and packing, export authorisation granted for each of these shipments,” said the source. “So the first deliveries, assuming the Indian government grants export authorisation, won’t happen until a few weeks from now.”

A WHO spokesperson said in an email that a new COVAX supply forecast would be published next week. SII and India’s health ministry did not respond to requests for comment.

The ministry said in a statement earlier in the day that Indian states had more than 159 million unutilised doses of various vaccines, as inoculations have slowed after 79% of the country’s 944 million adults got one dose and 37% got two doses.

SII CEO Adar Poonawalla told Reuters last month that the company could send 20 million to 30 million doses a month to COVAX in November and December, which would increase to “large volumes” from January once India’s own needs were met.

WHO chief Tedros Adhanom Ghebreyesus said on Friday that COVAX had the money and the contracts to buy vaccines for low-income countries but “manufacturers have not played their part”.

COVAX in September cut its 2021 delivery target by nearly 30% to 1.425 billion doses.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*